# Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

> **NCT04960709** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 712 (actual)

## Conditions studied

- Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Enfortumab Vedotin
- **PROCEDURE:** Radical Cystectomy

## Key facts

- **NCT ID:** NCT04960709
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-05
- **Primary completion:** 2026-04-30
- **Final completion:** 2028-09-08
- **Target enrollment:** 712 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04960709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04960709, "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04960709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*